142 related articles for article (PubMed ID: 26394083)
1. [Not Available].
Aktuelle Urol; 2015 Sep; 46(5):356-7. PubMed ID: 26394083
[No Abstract] [Full Text] [Related]
2. [First-line treatment for advanced renal cell carcinoma : A phase 3, open-label, randomized study of Atezolizumab (Anti-PD-L1-Antibody) in combination with Bevacizumab versus Sunitinib in patients with untreated advanced renal cell carcinoma ("IMmotion") - AN 37/15 der AUO].
Rexer H; Doehn C
Urologe A; 2016 Sep; 55(9):1242-3. PubMed ID: 27422311
[No Abstract] [Full Text] [Related]
3. Chromophobe renal cell carcinoma with prolonged response to sequential sunitinib and everolimus.
Larkin JM; Fisher RA; Pickering LM; Sohaib SA; Ghosn M; Christmas T; Cordiner RL; Gore ME
J Clin Oncol; 2011 Mar; 29(9):e241-2. PubMed ID: 21245426
[No Abstract] [Full Text] [Related]
4. Complete response after sequential sunitinib-sorafenib treatment in a patient with renal cell carcinoma: a case report.
Verzoni E; Lanocita R; Procopio G
Clin Genitourin Cancer; 2012 Jun; 10(2):130-3. PubMed ID: 22226825
[No Abstract] [Full Text] [Related]
5. Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma.
Rini BI; Stein M; Shannon P; Eddy S; Tyler A; Stephenson JJ; Catlett L; Huang B; Healey D; Gordon M
Cancer; 2011 Feb; 117(4):758-67. PubMed ID: 20922784
[TBL] [Abstract][Full Text] [Related]
6. Good response to second-line bevacizumab and interferon-alpha in a sunitinib-refractory patient with metastatic renal cell carcinoma.
Pastorelli D; Zustovich F; Faggioni G; Zovato S; Donach M; Nicoletto O; Farina M; Furini L; Ceravolo R; Carli P; Lombardi G
Anticancer Drugs; 2010 Feb; 21(2):210-3. PubMed ID: 19952729
[TBL] [Abstract][Full Text] [Related]
7. [Therapy of untreated local advanced or metastatic renal cell carcinoma. Phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in subjects with previously untreated, local advanced or metastatic renal cell carcinoma (CheckMate 214 - AN 36/15 of the AUO)].
Rexer H
Urologe A; 2015 Oct; 54(10):1443-5. PubMed ID: 26350358
[No Abstract] [Full Text] [Related]
8. Toxicity of sunitinib plus bevacizumab in renal cell carcinoma.
Rini BI; Garcia JA; Cooney MM; Elson P; Tyler A; Beatty K; Bokar J; Ivy P; Chen HX; Dowlati A; Dreicer R
J Clin Oncol; 2010 Jun; 28(17):e284-5; author reply e286-7. PubMed ID: 20439632
[No Abstract] [Full Text] [Related]
9. Targeted caval cytoreduction: solid foundations or shifting sands?
Bex A; Clarke N
Eur Urol; 2011 Jun; 59(6):919-20; discussion 921-2. PubMed ID: 21444147
[No Abstract] [Full Text] [Related]
10. A 51-year-old man with rapidly progressive metastatic sarcomatoid renal cell carcinoma: an apparent complete clinical response to second-line therapy with sunitinib and low-dose interferon-alpha.
Bradshaw MJ; Cheville JC; Croghan GA
Clin Adv Hematol Oncol; 2011 Jan; 9(1):61-4. PubMed ID: 21326149
[No Abstract] [Full Text] [Related]
11. From theoretical synergy to clinical supra-additive toxicity.
Soria JC; Massard C; Izzedine H
J Clin Oncol; 2009 Mar; 27(9):1359-61. PubMed ID: 19224836
[No Abstract] [Full Text] [Related]
12. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
Miller K; Bergmann L; Albers P; Gschwend J; Jäger E; Keilholz U
Aktuelle Urol; 2010 May; 41(3):193-6. PubMed ID: 20486036
[TBL] [Abstract][Full Text] [Related]
13. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
Golshayan AR; George S; Heng DY; Elson P; Wood LS; Mekhail TM; Garcia JA; Aydin H; Zhou M; Bukowski RM; Rini BI
J Clin Oncol; 2009 Jan; 27(2):235-41. PubMed ID: 19064974
[TBL] [Abstract][Full Text] [Related]
14. Salvage therapy with bevacizumab-sunitinib combination after failure of sunitinib alone for metastatic renal cell carcinoma: a case series.
Medioni J; Banu E; Helley D; Scotte F; Fournier L; Mejean A; Chedid A; Azizi M; Andrieu JM; Oudard S
Eur Urol; 2009 Jul; 56(1):207-11; quiz 211. PubMed ID: 19157688
[TBL] [Abstract][Full Text] [Related]
15. Combination of targeted agents in metastatic renal cell carcinoma: a path forward or a dead-end street?
Michaelson MD
Cancer; 2012 Apr; 118(7):1744-6. PubMed ID: 21898374
[No Abstract] [Full Text] [Related]
16. Management of bone metastases from advanced renal cell carcinoma.
Khattak MA; Martin HL
Eur J Cancer; 2012 Nov; 48(16):3123-5. PubMed ID: 22682018
[No Abstract] [Full Text] [Related]
17. A cross-over response to sequential use of sunitinib after sorafenib in a patient with metastatic renal cell carcinoma.
Richards TM; Plowman PN; Reznek R; Ball SA
Clin Oncol (R Coll Radiol); 2009 Oct; 21(8):633-4. PubMed ID: 19380217
[No Abstract] [Full Text] [Related]
18. Kidney cancer: SWITCHing inconsequential.
Thoma C
Nat Rev Urol; 2015 Jun; 12(6):305. PubMed ID: 25986758
[No Abstract] [Full Text] [Related]
19. The Complete Response to Targeted Drugs Without Surgery or Radiotherapy: A Case of Pituitary Metastasis From Renal Cell Carcinoma.
Payandeh M; Sadeghi M; Sadeghi E
Acta Med Iran; 2016 Sep; 54(9):617-619. PubMed ID: 27832697
[TBL] [Abstract][Full Text] [Related]
20. Effective therapy for metastatic renal cancer, whither to now.
Stadler WM
J Clin Oncol; 2009 Aug; 27(22):3573-4. PubMed ID: 19487371
[No Abstract] [Full Text] [Related]
[Next] [New Search]